Atreca and Xencor to Develop T-Cell Engaging Bispecific Antibody
Tuesday, February 07, 2023
Atreca, and Xencor as part of their existing strategic collaboration, have mutually selected the first programme combining an Atreca-discovered antibody with Xencor’s XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).
Under the terms of 2020 collaboration, Atreca generates novel, tumour-binding antibodies from the immune responses of cancer patients and identifies the antibodies’ targets. Xencor engineers Atreca’s antibodies into T-cell engaging bispecific antibodies that bind to and activate the CD3 co-receptor on T cells, and characterises these novel XmAb bispecific antibodies to identify candidates for further development. The programme announced is the first of up to two joint programmes mutually selected for further development and commercialisation, with each partner sharing 50% of costs and profits. Atreca leads the clinical development, regulatory and commercialisation activities for this programme, and the second potential joint programme will be advanced by Xencor. In addition, the agreement allows for each partner to pursue up to two programmes arising out of the collaboration independently.
The use of modular protein engineering platforms allows to create a new generation of XmAb bispecific antibodies that acts directly and selectively against solid tumours with cytotoxic T cell engagement.
